Breaking News Instant updates and real-time market news.

VCNX

Vaccinex

$1.02 /

-0.03 (-2.86%)

11:05
08/08/22
08/08
11:05
08/08/22
11:05

Vaccinex announces publication of results of Phase 2 SIGNAL study

Vaccinex announced that results of its Phase 2 SIGNAL study to evaluate its SEMA4D-blocking antibody, pepinemab, in patients with Huntington's Disease were published in the August 8, 2022 issue of Nature Medicine. In parallel, a second report has been published in the Journal of Neuroinflammation2 detailing the pathologic impact of SEMA4D on neuroinflammatory cells in both HD and Alzheimer's disease. The Nature Medicine article, titled "Pepinemab antibody blockade of SEMA4D in early Huntington's Disease: a randomized, placebo-controlled, Phase 2 trial," provides a comprehensive analysis of results from the Phase 2 study showing that while the trial did not meet its pre-specified primary efficacy endpoints, brain imaging measures showed a significant reduction in atrophy of the brain caudate nucleus and prevented loss of metabolic activity in most brain regions. Multiple other exploratory and post-hoc assessments indicate a cognitive benefit to treatment. Pepinemab was well-tolerated by participants in the trial. The Journal of Neuroinflammation article, titled "Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity," demonstrates that SEMA4D is upregulated on neurons that are stressed or damaged during HD and AD disease progression and this triggers physiological changes in astrocytes that reduce their ability to facilitate energy metabolism in the brain and to control levels of neurotransmitters required for efficient signaling. Experiments in an animal model of Alzheimer's disease demonstrate that treatment with SEMA4D-blocking antibody inhibits reactive transformation of astrocytes, restores neuronal transmitters, and prevents or reduces cognitive deficits. These findings encourage continued development of pepinemab as a potential therapy for patients with early manifest symptoms of HD and potentially AD. Accordingly, a phase 1b/2a study of pepinemab in Alzheimer's disease has been initiated and is actively enrolling patients. The mechanism of action of pepinemab, targeting neuroinflammation, may provide an alternative to other AD therapies that target aggregates of Abeta amyloid. Summary of Key Findings from the SIGNAL HD trial Highlighted in the Nature Medicine Article: The Nature Medicine article highlights results that support the potential of pepinemab as a novel therapeutic approach for treating cognitive impairment in patients with HD, particularly those initially presenting with mild cognitive deficits. Key Findings from the Phase 2 SIGNAL HD trial include: significantly improved cognition in patients with early manifest disease, as reflected in the HD-Cognitive Assessment Battery of 6 different cognitive measures; significantly reduced apathy severity (p=0.02), measured by the Problem Behaviors Assessment which has previously been reported to correlate with cognitive decline. reduced atrophy in the caudate nucleus, a brain region known to undergo early degeneration in HD. significantly improved brain metabolic activity as detected by FDG-PET in the majority of brain regions examined. FDG-PET signal has been reported to correlate with cognitive decline and clinical progression in AD. was well-tolerated with a low frequency of treatment-emergent adverse events and a low treatment discontinuation rate over the 18-month treatment period. SIGNAL was a phase 2, multi-center, randomized, double-blinded, placebo-controlled clinical trial in 265 subjects including 179 early manifest and 86 late prodromal subjects all confirmed to carry the Huntington's disease mutation. Subjects were randomized 1:1 for monthly intravenous infusion with either 20 mg/kg pepinemab or placebo for at least 18 months at 32 centers in the U.S. and Canada. The study is now complete, and we believe the program is Phase 3-ready.

OTHER BREAKING NEWS FROM THE FLY

Syndicate
Momentus launches 3-year $50M at-the-market equity program » 17:39
09/28/22
09/28
17:39
09/28/22
17:39
MNTS

Momentus

$1.50 /

+0.1 (+7.14%)

Momentus "announces…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MNTS Momentus
$1.50 /

+0.1 (+7.14%)

MNTS Momentus
$1.50 /

+0.1 (+7.14%)

07/05/22 Evercore ISI
Momentus initiated with an Underperform at Evercore ISI
05/23/22 Deutsche Bank
Momentus named short-term buy idea at Deutsche Bank
05/11/22 Deutsche Bank
Momentus price target lowered to $7 from $8 at Deutsche Bank
03/23/22 Deutsche Bank
SpaceX decision 'clear positive' for Momentus, says Deutsche Bank
MNTS Momentus
$1.50 /

+0.1 (+7.14%)

MNTS Momentus
$1.50 /

+0.1 (+7.14%)

Earnings
Volta withdraws FY22 revenue guidance  17:38
09/28/22
09/28
17:38
09/28/22
17:38
VLTA

Volta

$1.57 /

+0.055 (+3.64%)

 
ShowHide Related Items >><<
VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

08/09/22 Roth Capital
Volta downgraded to Neutral from Buy at Roth Capital
08/04/22 Barclays
Volta initiated with an Equal Weight at Barclays
06/13/22 Cantor Fitzgerald
Volta downgraded to Neutral at Cantor Fitzgerald as CFO departs
06/13/22 Cantor Fitzgerald
Volta downgraded to Neutral from Overweight at Cantor Fitzgerald
VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

Earnings
Volta lowers Q3 revenue view to $13.5M-$14.5M from $17M-$19M, consensus $17.56M  17:38
09/28/22
09/28
17:38
09/28/22
17:38
VLTA

Volta

$1.57 /

+0.055 (+3.64%)

 
ShowHide Related Items >><<
VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

08/09/22 Roth Capital
Volta downgraded to Neutral from Buy at Roth Capital
08/04/22 Barclays
Volta initiated with an Equal Weight at Barclays
06/13/22 Cantor Fitzgerald
Volta downgraded to Neutral at Cantor Fitzgerald as CFO departs
06/13/22 Cantor Fitzgerald
Volta downgraded to Neutral from Overweight at Cantor Fitzgerald
VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

Hot Stocks
Volta announces organizational restructuring, 10% workforce reduction » 17:36
09/28/22
09/28
17:36
09/28/22
17:36
VLTA

Volta

$1.57 /

+0.055 (+3.64%)

Volta announced an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

08/09/22 Roth Capital
Volta downgraded to Neutral from Buy at Roth Capital
08/04/22 Barclays
Volta initiated with an Equal Weight at Barclays
06/13/22 Cantor Fitzgerald
Volta downgraded to Neutral at Cantor Fitzgerald as CFO departs
06/13/22 Cantor Fitzgerald
Volta downgraded to Neutral from Overweight at Cantor Fitzgerald
VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

Syndicate
Jupiter Wellness files $100M mixed securities shelf  17:36
09/28/22
09/28
17:36
09/28/22
17:36
JUPW

Jupiter Wellness

/

+

 
ShowHide Related Items >><<
JUPW Jupiter Wellness
/

+

JUPW Jupiter Wellness
/

+

Hot Stocks
Neogen jumps 5% to $15.13 after insider buy  17:33
09/28/22
09/28
17:33
09/28/22
17:33
NEOG

Neogen

$14.42 /

+0.15 (+1.05%)

 
ShowHide Related Items >><<
NEOG Neogen
$14.42 /

+0.15 (+1.05%)

NEOG Neogen
$14.42 /

+0.15 (+1.05%)

09/27/22 Piper Sandler
Neogen quarter 'somewhat disappointing,' says Piper Sandler
08/30/22 Piper Sandler
Neogen price target lowered to $20 from $26 at Piper Sandler
08/01/22 Piper Sandler
Neogen price target raised to $26 from $25 at Piper Sandler
07/11/22 Piper Sandler
Neogen initiated with a Neutral at Piper Sandler
NEOG Neogen
$14.42 /

+0.15 (+1.05%)

NEOG Neogen
$14.42 /

+0.15 (+1.05%)

NEOG Neogen
$14.42 /

+0.15 (+1.05%)

Hot Stocks
Neogen CEO buys $316K in common stock » 17:32
09/28/22
09/28
17:32
09/28/22
17:32
NEOG

Neogen

$14.42 /

+0.15 (+1.05%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NEOG Neogen
$14.42 /

+0.15 (+1.05%)

NEOG Neogen
$14.42 /

+0.15 (+1.05%)

09/27/22 Piper Sandler
Neogen quarter 'somewhat disappointing,' says Piper Sandler
08/30/22 Piper Sandler
Neogen price target lowered to $20 from $26 at Piper Sandler
08/01/22 Piper Sandler
Neogen price target raised to $26 from $25 at Piper Sandler
07/11/22 Piper Sandler
Neogen initiated with a Neutral at Piper Sandler
NEOG Neogen
$14.42 /

+0.15 (+1.05%)

NEOG Neogen
$14.42 /

+0.15 (+1.05%)

NEOG Neogen
$14.42 /

+0.15 (+1.05%)

Hot Stocks
5E Advanced Metals CEO Henri Tausch to resign » 17:31
09/28/22
09/28
17:31
09/28/22
17:31
FEAM

5E Advanced Metals

$15.63 /

+0.92 (+6.25%)

5E Advanced Materials…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FEAM 5E Advanced Metals
$15.63 /

+0.92 (+6.25%)

FEAM 5E Advanced Metals
$15.63 /

+0.92 (+6.25%)

06/09/22 Baird
Baird starts 5E Advanced Metals at Outperform, sees opportunity for market gains
06/09/22 Baird
5E Advanced Metals initiated with an Outperform at Baird
05/24/22 DA Davidson
5E Advanced Metals price target raised to $36 from $30 at DA Davidson
04/07/22 DA Davidson
5E Advanced Metals initiated with a Buy at DA Davidson
FEAM 5E Advanced Metals
$15.63 /

+0.92 (+6.25%)

Initiation
Synopsys initiated with a Buy at Deutsche Bank » 17:31
09/28/22
09/28
17:31
09/28/22
17:31
SNPS

Synopsys

$313.28 /

+7.4 (+2.42%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNPS Synopsys
$313.28 /

+7.4 (+2.42%)

SNPS Synopsys
$313.28 /

+7.4 (+2.42%)

09/07/22 Stifel
Stifel starts Cadence Design at Hold, prefers Synopsys on valuation basis
09/07/22 Stifel
Stifel starts Synopsys at Buy on market leading position in EDA and valuation
09/07/22 Stifel
Synopsys initiated with a Buy at Stifel
08/18/22 KeyBanc
Synopsys price target raised to $455 from $445 at KeyBanc
SNPS Synopsys
$313.28 /

+7.4 (+2.42%)

SNPS Synopsys
$313.28 /

+7.4 (+2.42%)

SNPS Synopsys
$313.28 /

+7.4 (+2.42%)

SNPS Synopsys
$313.28 /

+7.4 (+2.42%)

Hot Stocks
Ovintiv renews buyback program » 17:31
09/28/22
09/28
17:31
09/28/22
17:31
OVV

Ovintiv

$44.68 /

+3.315 (+8.01%)

Ovintiv "announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OVV Ovintiv
$44.68 /

+3.315 (+8.01%)

OVV Ovintiv
$44.68 /

+3.315 (+8.01%)

09/26/22 Barclays
Ovintiv price target raised to $78 from $75 at Barclays
09/21/22 Citi
Ovintiv price target raised to $65 from $57 at Citi
09/20/22 BofA
Ovintiv price target raised to $70 from $60 at BofA
09/19/22 RBC Capital
Ovintiv price target raised to $56 from $51 at RBC Capital
OVV Ovintiv
$44.68 /

+3.315 (+8.01%)

OVV Ovintiv
$44.68 /

+3.315 (+8.01%)

Conference/Events
Jefferies software/Internet analyst to hold analyst/industry conference call » 17:28
09/28/22
09/28
17:28
09/28/22
17:28
ADBE

Adobe

$281.39 /

+4.005 (+1.44%)

Software & Internet…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ADBE Adobe
$281.39 /

+4.005 (+1.44%)

ADBE Adobe
$281.39 /

+4.005 (+1.44%)

09/22/22 MoffettNathanson
Adobe initiated with a Hold at MoffettNathanson
09/19/22 Wells Fargo
Wells Fargo downgrades Adobe to Equal Weight, lowers price target to $310
09/19/22 Edward Jones
Adobe downgraded to Hold from Buy at Edward Jones
09/19/22 Wells Fargo
Adobe downgraded to Equal Weight from Overweight at Wells Fargo
ADBE Adobe
$281.39 /

+4.005 (+1.44%)

ADBE Adobe
$281.39 /

+4.005 (+1.44%)

ADBE Adobe
$281.39 /

+4.005 (+1.44%)

ADBE Adobe
$281.39 /

+4.005 (+1.44%)

Conference/Events
Neurocrine to participate in a conference call with JPMorgan » 17:21
09/28/22
09/28
17:21
09/28/22
17:21
NBIX

Neurocrine

$102.82 /

+1.39 (+1.37%)

SMid Cap Biotech Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

09/26/22 Wells Fargo
Neurocrine initiated with an Equal Weight at Wells Fargo
08/08/22 Mizuho
Neurocrine price target raised to $98 from $95 at Mizuho
08/05/22 Baird
Neurocrine price target raised to $125 from $117 at Baird
08/05/22 Barclays
Neurocrine price target raised to $113 from $110 at Barclays
NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

NBIX Neurocrine
$102.82 /

+1.39 (+1.37%)

Hot Stocks
Raytheon Technologies awarded $277.92M Navy contract modification » 17:20
09/28/22
09/28
17:20
09/28/22
17:20
RTX

Raytheon Technologies

$83.29 /

+2.335 (+2.88%)

Raytheon Technologies was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RTX Raytheon Technologies
$83.29 /

+2.335 (+2.88%)

RTX Raytheon Technologies
$83.29 /

+2.335 (+2.88%)

07/27/22 Wells Fargo
Raytheon Technologies price target lowered to $98 from $106 at Wells Fargo
07/27/22 RBC Capital
Raytheon Technologies price target lowered to $115 from $125 at RBC Capital
04/27/22 Argus
Raytheon Technologies price target raised to $112 from $100 at Argus
04/27/22 Cowen
Raytheon Technologies price target raised to $120 from $115 at Cowen
RTX Raytheon Technologies
$83.29 /

+2.335 (+2.88%)

RTX Raytheon Technologies
$83.29 /

+2.335 (+2.88%)

RTX Raytheon Technologies
$83.29 /

+2.335 (+2.88%)

RTX Raytheon Technologies
$83.29 /

+2.335 (+2.88%)

Hot Stocks
Prologis, Duke Realty shareholders approve merger » 17:16
09/28/22
09/28
17:16
09/28/22
17:16
PLD

Prologis

$103.89 /

+1.69 (+1.65%)

, DRE

Duke Realty

$49.28 /

+0.87 (+1.80%)

Prologis (PLD) and Duke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PLD Prologis
$103.89 /

+1.69 (+1.65%)

DRE Duke Realty
$49.28 /

+0.87 (+1.80%)

PLD Prologis
$103.89 /

+1.69 (+1.65%)

07:43 Today BMO Capital
Prologis price target lowered to $130 from $135 at BMO Capital
09/27/22 BMO Capital
Prologis price target lowered to $130 from $135 at BMO Capital
09/27/22 Evercore ISI
Prologis upgraded to Outperform at Evercore ISI following pullback
09/27/22 Evercore ISI
Prologis upgraded to Outperform from In Line at Evercore ISI
DRE Duke Realty
$49.28 /

+0.87 (+1.80%)

07/15/22 Baird
Duke Realty downgraded to Neutral into takeover at Baird
07/14/22 Baird
Duke Realty downgraded to Neutral from Outperform at Baird
06/14/22 Edward Jones
Duke Realty downgraded to Hold from Buy at Edward Jones
05/31/22 Truist
Duke Realty price target lowered to $56 from $63 at Truist
PLD Prologis
$103.89 /

+1.69 (+1.65%)

DRE Duke Realty
$49.28 /

+0.87 (+1.80%)

PLD Prologis
$103.89 /

+1.69 (+1.65%)

PLD Prologis
$103.89 /

+1.69 (+1.65%)

DRE Duke Realty
$49.28 /

+0.87 (+1.80%)

PLD Prologis
$103.89 /

+1.69 (+1.65%)

DRE Duke Realty
$49.28 /

+0.87 (+1.80%)

Initiation
Cadence Design initiated with a Buy at Deutsche Bank » 17:15
09/28/22
09/28
17:15
09/28/22
17:15
CDNS

Cadence Design

$167.00 /

+3.83 (+2.35%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CDNS Cadence Design
$167.00 /

+3.83 (+2.35%)

CDNS Cadence Design
$167.00 /

+3.83 (+2.35%)

09/07/22 Stifel
Stifel starts Cadence Design at Hold, prefers Synopsys on valuation basis
09/07/22 Stifel
Cadence Design initiated with a Hold at Stifel
08/16/22 Wolfe Research
Cadence Design initiated with an Outperform at Wolfe Research
07/26/22 Needham
Cadence Design price target raised to $200 from $193 at Needham
CDNS Cadence Design
$167.00 /

+3.83 (+2.35%)

CDNS Cadence Design
$167.00 /

+3.83 (+2.35%)

CDNS Cadence Design
$167.00 /

+3.83 (+2.35%)

Hot Stocks
Angel Oak Mortgage appoints Sreeni Prabhu as CEO and President » 17:13
09/28/22
09/28
17:13
09/28/22
17:13
AOMR

Angel Oak Mortgage

$12.44 /

+0.17 (+1.39%)

Angel Oak Mortgage…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AOMR Angel Oak Mortgage
$12.44 /

+0.17 (+1.39%)

AOMR Angel Oak Mortgage
$12.44 /

+0.17 (+1.39%)

07/21/22 B. Riley
Angel Oak Mortgage price target lowered to $19 from $22 at B. Riley
06/01/22 UBS
Angel Oak Mortgage downgraded to Neutral from Buy at UBS
11/10/21 Oppenheimer
Angel Oak Mortgage downgraded on lack of earnings growth at Oppenheimer
11/10/21 Oppenheimer
Angel Oak Mortgage downgraded to Perform from Outperform at Oppenheimer
AOMR Angel Oak Mortgage
$12.44 /

+0.17 (+1.39%)

Syndicate
Invivyd files $400M mixed securities shelf  17:11
09/28/22
09/28
17:11
09/28/22
17:11
IVVD

Invivyd

$3.17 /

+0.07 (+2.26%)

 
ShowHide Related Items >><<
IVVD Invivyd
$3.17 /

+0.07 (+2.26%)

IVVD Invivyd
$3.17 /

+0.07 (+2.26%)

Syndicate
Connexa Sports Technologies announces $5.0M private placement » 17:07
09/28/22
09/28
17:07
09/28/22
17:07
CNXA

Connexa Sports Technologies

/

+

Connexa Sports…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CNXA Connexa Sports Technologies
/

+

Downgrade
Cognyte downgraded to Hold from Buy at Stifel » 17:02
09/28/22
09/28
17:02
09/28/22
17:02
CGNT

Cognyte

$4.73 /

+0.32 (+7.26%)

Stifel analyst Brad…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CGNT Cognyte
$4.73 /

+0.32 (+7.26%)

06/29/22 Evercore ISI
Cognyte downgraded to In Line at Evercore ISI after 'disappointing' results
06/29/22 Evercore ISI
Cognyte downgraded to In Line from Outperform at Evercore ISI
06/28/22 William Blair
Cognyte downgraded on lack of revenue visibility at William Blair
06/28/22 William Blair
Cognyte downgraded to Market Perform from Outperform at William Blair
CGNT Cognyte
$4.73 /

+0.32 (+7.26%)

CGNT Cognyte
$4.73 /

+0.32 (+7.26%)

Initiation
Truist starts QuantumScape at Hold, upside limited as large volumes years away » 16:59
09/28/22
09/28
16:59
09/28/22
16:59
QS

QuantumScape

$9.22 /

+0.1 (+1.10%)

Truist analyst Jordan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
QS QuantumScape
$9.22 /

+0.1 (+1.10%)

QS QuantumScape
$9.22 /

+0.1 (+1.10%)

16:13 Today Truist
QuantumScape initiated with a Hold at Truist
07/28/22 Deutsche Bank
QuantumScape price target lowered to $13 from $20 at Deutsche Bank
07/14/22 Morgan Stanley
QuantumScape price target lowered to $12 from $30 at Morgan Stanley
04/12/22 Deutsche Bank
QuantumScape initiated with a Hold at Deutsche Bank
QS QuantumScape
$9.22 /

+0.1 (+1.10%)

QS QuantumScape
$9.22 /

+0.1 (+1.10%)

QS QuantumScape
$9.22 /

+0.1 (+1.10%)

Initiation
Truist starts TuSimple at Buy, says valuation fails to reflect its 'massive' TAM » 16:55
09/28/22
09/28
16:55
09/28/22
16:55
TSP

TuSimple

$8.03 /

+0.435 (+5.73%)

Truist analyst Jordan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSP TuSimple
$8.03 /

+0.435 (+5.73%)

TSP TuSimple
$8.03 /

+0.435 (+5.73%)

16:14 Today Truist
TuSimple initiated with a Buy at Truist
08/03/22 Baird
TuSimple price target lowered to $11 from $17 at Baird
07/08/22 Morgan Stanley
TuSimple price target lowered to $35 from $45 at Morgan Stanley
05/26/22 China Renaissance
TuSimple upgraded to Buy from Hold at China Renaissance
TSP TuSimple
$8.03 /

+0.435 (+5.73%)

TSP TuSimple
$8.03 /

+0.435 (+5.73%)

TSP TuSimple
$8.03 /

+0.435 (+5.73%)

Earnings
PG&E backs FY22 core EPS view $1.07-$1.13, consensus $1.10  16:53
09/28/22
09/28
16:53
09/28/22
16:53
PCG

PG&E

$12.70 /

+0.295 (+2.38%)

 
ShowHide Related Items >><<
PCG PG&E
$12.70 /

+0.295 (+2.38%)

PCG PG&E
$12.70 /

+0.295 (+2.38%)

09/26/22 Morgan Stanley
PG&E continues 'positive momentum' with S&P inclusion, says Morgan Stanley
07/18/22 Barclays
PG&E price target lowered to $16 from $17 at Barclays
04/25/22 Credit Suisse
PG&E initiated with an Outperform at Credit Suisse
04/12/22 Mizuho
PG&E price target raised to $18 from $16 at Mizuho
PCG PG&E
$12.70 /

+0.295 (+2.38%)

  • 01
    Feb
PCG PG&E
$12.70 /

+0.295 (+2.38%)

PCG PG&E
$12.70 /

+0.295 (+2.38%)

PCG PG&E
$12.70 /

+0.295 (+2.38%)

Initiation
Truist starts Proterra at Buy, positive on commercial EV battery niche » 16:53
09/28/22
09/28
16:53
09/28/22
16:53
PTRA

Proterra

$5.15 /

+0.29 (+5.97%)

Truist analyst Jordan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PTRA Proterra
$5.15 /

+0.29 (+5.97%)

PTRA Proterra
$5.15 /

+0.29 (+5.97%)

16:14 Today Truist
Proterra initiated with a Buy at Truist
06/01/22 DA Davidson
Proterra initiated with a Buy at DA Davidson
05/19/22 Barclays
Proterra price target lowered to $6 from $8 at Barclays
05/16/22 Citi
Proterra price target lowered to $6.50 from $8.50 at Citi
PTRA Proterra
$5.15 /

+0.29 (+5.97%)

PTRA Proterra
$5.15 /

+0.29 (+5.97%)

Hot Stocks
PG&E seeks CPUC approval to sell stake in power plants » 16:52
09/28/22
09/28
16:52
09/28/22
16:52
PCG

PG&E

$12.70 /

+0.295 (+2.38%)

According to a regulatory…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PCG PG&E
$12.70 /

+0.295 (+2.38%)

PCG PG&E
$12.70 /

+0.295 (+2.38%)

09/26/22 Morgan Stanley
PG&E continues 'positive momentum' with S&P inclusion, says Morgan Stanley
07/18/22 Barclays
PG&E price target lowered to $16 from $17 at Barclays
04/25/22 Credit Suisse
PG&E initiated with an Outperform at Credit Suisse
04/12/22 Mizuho
PG&E price target raised to $18 from $16 at Mizuho
PCG PG&E
$12.70 /

+0.295 (+2.38%)

  • 01
    Feb
PCG PG&E
$12.70 /

+0.295 (+2.38%)

PCG PG&E
$12.70 /

+0.295 (+2.38%)

PCG PG&E
$12.70 /

+0.295 (+2.38%)

Syndicate
Altus Power 7M share Spot Secondary; price range $11.25-$12.00 » 16:52
09/28/22
09/28
16:52
09/28/22
16:52
AMPS

Altus Power

$14.23 /

+0.34 (+2.45%)

JPMorgan, Citi and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMPS Altus Power
$14.23 /

+0.34 (+2.45%)

AMPS Altus Power
$14.23 /

+0.34 (+2.45%)

08/18/22 Morgan Stanley
Altus Power price target raised to $12.50 from $10 at Morgan Stanley
08/08/22 JPMorgan
Altus Power price target raised to $11 from $9 at JPMorgan
07/18/22 JPMorgan
Altus Power initiated with a Neutral at JPMorgan
06/15/22 Citi
Citi still likes Altus Power in current environment
AMPS Altus Power
$14.23 /

+0.34 (+2.45%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.